{"id":251241,"date":"2021-12-29T00:00:00","date_gmt":"2021-12-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidid0026-biopharma-hepatitis-c-virus-epidemiology-middle-east\/"},"modified":"2026-03-31T10:41:21","modified_gmt":"2026-03-31T10:41:21","slug":"epidid0026-biopharma-hepatitis-c-virus-epidemiology-middle-east-africa-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0026-biopharma-hepatitis-c-virus-epidemiology-middle-east-africa-data\/","title":{"rendered":"Hepatitis C Virus &#8211; Epidemiology &#8211; Middle East &#038; Africa Data"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of hepatitis c virus (<abbr title=\"hepatitis C virus\">HCV<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of <abbr title=\"hepatitis C virus\">HCV<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"hepatitis C virus\">HCV<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr title=\"hepatitis C virus\">HCV<\/abbr> per year?<\/li>\n<li>How will improvements in survival change the number of people living with <abbr title=\"hepatitis C virus\">HCV<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"hepatitis C virus\">HCV<\/abbr>, how many in each country have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"hepatitis C virus\">HCV<\/abbr>, how many in each country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"hepatitis C virus\">HCV<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts 49 <abbr title=\"hepatitis C virus\">HCV<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed GT3 viremic noncirrhotic prevalent cases.<\/li>\n<li>Viremic cirrhotic prevalent cases.<\/li>\n<li>Drug-treated GT3 viremic noncirrhotic sustained virologic response (<abbr title=\"sustained virologic response\">SVR<\/abbr>) events.<\/li>\n<li>Drug-treated GT2 viremic cirrhotic events.<\/li>\n<li>Viremic noncirrhotic prevalent cases.<\/li>\n<li>Diagnosed GT2 viremic cirrhotic prevalent cases.<\/li>\n<li>GT3 viremic prevalent cases.<\/li>\n<li>Drug-treated GT4+ viremic noncirrhotic events.<\/li>\n<li>Drug-treated GT3 viremic cirrhotic <abbr title=\"sustained virologic response\">SVR<\/abbr> events.<\/li>\n<li>Drug-treated GT1 viremic noncirrhotic events.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251241","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-product-epidemiology","biopharma-geography-middle-east-africa","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251241\/revisions"}],"predecessor-version":[{"id":576295,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251241\/revisions\/576295"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}